NEWS
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Windtree Therapeutics (NASDAQ: WINT) announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients with early cardiogenic shock. The study met its primary endpoint, significantly improving systolic blood pressure over six hours compared to placebo. Key findings include:
- Improved cardiac output by ~15% in the istaroxime group
- Reduced pulmonary capillary wedge pressure
- Enhanced mixed venous oxygen saturation
- Improved renal function
- Decreased NYHA heart failure classification severity
- Reduced incidence of worsening heart failure as a serious adverse event
The safety profile was generally consistent with previous istaroxime trials, with no increase in clinically significant arrhythmias compared to placebo. These results support istaroxime's potential as a novel therapy for early cardiogenic shock and acute heart failure.
- Improved cardiac output by ~15% in the istaroxime group
- Reduced pulmonary capillary wedge pressure
- Enhanced mixed venous oxygen saturation
- Improved renal function
- Decreased NYHA heart failure classification severity
- Reduced incidence of worsening heart failure as a serious adverse event
The safety profile was generally consistent with previous istaroxime trials, with no increase in clinically significant arrhythmias compared to placebo. These results support istaroxime's potential as a novel therapy for early cardiogenic shock and acute heart failure.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2498Followers
107Following
27KVisitors
Follow
Marliana : I’m getting this stock.